Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors

Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors

Abstract Background Immune checkpoint inhibitors (anti-CTLA-4, anti-PD-1, or the combination) enhance anti-tumor immune responses, yielding durable clinical benefit in several cancer types, including melanoma. However, a subset of patients experience immune-related adverse events (irAEs), which can...

Full description

Bibliographic Details
Main Authors: Michael F. Gowen, Keith M. Giles, Danny Simpson, Jeremy Tchack, Hua Zhou, Una Moran, Zarmeena Dawood, Anna C. Pavlick, Shaohui Hu, Melissa A. Wilson, Hua Zhong, Michelle Krogsgaard, Tomas Kirchhoff, Iman Osman
Format: Article
Language:English
Published: BMC 2018-04-01
Series:Journal of Translational Medicine
Subjects:
Melanoma
Immunotherapy
Antibodies
Toxicity
Biomarker
Online Access:http://link.springer.com/article/10.1186/s12967-018-1452-4

Internet

http://link.springer.com/article/10.1186/s12967-018-1452-4

Similar Items